Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

COX-2 inhibitor selected for further study at Searle

May 24, 1996

Ciba-Geigy claims matrix metalloproteinase inhibitors

May 24, 1996

SmithKline Beecham's C-DART approach to rheumatoid arthritis

May 17, 1996

Novel antiarthritics claimed by Procter & Gamble

May 17, 1996

British Biotech reveals metalloproteinase inhibitors

May 17, 1996

COX-2 inhibitors claimed by Searle

May 17, 1996

Hoechst claims treatment for chronic polyarthritis

May 10, 1996

FR-133605 effective in preclinical models of rheumatoid arthritis, septic shock

May 3, 1996

Fujisawa reports collagenase inhibitors

May 3, 1996

Searle and Yamanouchi to codevelop celecoxib

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...